GILD

Gilead Sciences, Inc. Press Releases

$117.86
*  
0.04
0.03%
Get GILD Alerts
*Delayed - data as of Jul. 31, 2015  -  Find a broker to begin trading GILD now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By

Gilead Sciences Announces Third Quarter 2015 Dividend
7/28/2015 4:02:00 PM - Business Wire
▲1.60 % Price Change since this news event. The Volume Ratio is 2.31.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Sciences Announces Second Quarter 2015 Financial Results
7/28/2015 4:01:00 PM - Business Wire
▲2.49 % Price Change since this news event. The Volume Ratio is 2.32.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Announces Executive Promotions
7/27/2015 4:30:00 PM - Business Wire
▲6.42 % Price Change since this news event. The Volume Ratio is 1.61.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Sciences to Release Second Quarter 2015 Financial Results on Tuesday, July 28, 2015
7/21/2015 5:00:00 PM - Business Wire
▲0.51 % Price Change since this news event. The Volume Ratio is 1.08.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF)
7/21/2015 2:06:00 PM - Business Wire
▲0.36 % Price Change since this news event. The Volume Ratio is 2.23.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Harvoni®, the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C
7/3/2015 2:00:00 AM - Business Wire
▲2.40 % Price Change since this news event. The Volume Ratio is 2.34.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF)
7/1/2015 4:30:00 PM - Business Wire
▲1.59 % Price Change since this news event. The Volume Ratio is 1.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 9
6/8/2015 5:00:00 PM - Business Wire
▲3.65 % Price Change since this news event. The Volume Ratio is 1.17.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Zydelig® in Combination With Ofatumumab Improves Progression-Free Survival in Previously-Treated Patients With Chronic Lymphocytic Leukemia
5/31/2015 9:00:00 AM - Business Wire
▲4.88 % Price Change since this news event. The Volume Ratio is 1.13.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment
5/28/2015 8:30:00 AM - Business Wire
▲5.08 % Price Change since this news event. The Volume Ratio is 1.06.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Sciences to Present at the Bernstein 31st Annual Strategic Decisions Conference on Thursday, May 28
5/27/2015 5:00:00 PM - Business Wire
▲4.74 % Price Change since this news event. The Volume Ratio is 1.05.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Patent Challenges In Five Countries Dispute Validity Of Gilead's Claims To Hep C Drug Patents That Block Treatment For Up To 59 Million People
5/20/2015 9:00:00 AM - PR Newswire
▲7.03 % Price Change since this news event. The Volume Ratio is 0.99.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Sciences to Present at the UBS 2015 Global Healthcare Conference on Tuesday, May 19
5/18/2015 5:00:00 PM - Business Wire
▲6.22 % Price Change since this news event. The Volume Ratio is 0.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Sciences to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13
5/12/2015 5:00:00 PM - Business Wire
▲11.64 % Price Change since this news event. The Volume Ratio is 1.85.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Sciences Acquires EpiTherapeutics
5/6/2015 8:30:00 AM - Business Wire